Philip Katz, MD
Gastroenterology · Ny, NYNPI 1124097340
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (55.5%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 18 manufacturers reported payments, led by Phathom Pharmaceuticals, Inc. at 35.7% of the total. Reporting peaked in 2023 at $10,730 and has fallen 74.2% since, to $2,767 in 2025.
Across 41 payments — averaging $588.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Phathom Pharmaceuticals, Inc.$9K
- Covidien LP$5K
- Braintree Laboratories, Inc.$3K
- AstraZeneca$2K
- Medtronic$2K
- Takeda Pharmaceuticals U.S.A., Inc.$2K
- plus $787 from 12 others
Across 5 payments — averaging $1674.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ironwood Pharmaceuticals, Inc$8K
What the payments were for
- Consulting fees$7,58831%
- Speaking & faculty fees$13,40056%
- Travel & lodging$1,3886%
- Food & beverage$1,7507%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Phathom Pharmaceuticals, Inc. | 12 | $8,612 |
| Covidien LP | 5 | $4,759 |
| Braintree Laboratories, Inc. | 2 | $3,383 |
| AstraZeneca | 2 | $2,269 |
| Medtronic | 4 | $2,176 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $2,140 |
| Lucid Diagnostics Inc. | 2 | $176 |
| Merit Medical Systems Inc | 1 | $130 |
| QOL Medical, LLC | 1 | $125 |
| Laborie Medical Technologies Corp. | 1 | $70 |
| Boston Scientific | 1 | $57 |
| AbbVie | 3 | $50 |
| Endogastric Solutions, Inc | 1 | $48 |
| Regeneron Healthcare Solutions, Inc. | 1 | $43 |
| Pentax Of America, Inc. | 1 | $31 |
| Pfizer | 1 | $25 |
| Lilly USA, LLC | 1 | $18 |
| Atmo Biosciences Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VOQUEZNA$7,122
- VOQUEZNA TRIPLE PAK$6,000
- VOQUEZNA DUAL PAK$6,000
- Bravo$2,945
- FASENRA$2,269
- Beacon$2,000
- Emprint$1,600
- ESOPHYX$130
- Sucraid$125
How this compares
$24,126 in reported general payments places this provider in the 85th percentile of 1,682 gastroenterology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Pantoprazole Sodium | 25 | $1,698 |
| Omeprazole | 57 | $479 |
| Famotidine | 16 | $198 |
| Dicyclomine Hcl | 11 | $190 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in Ny
- David Carr LockeNew York$2M
- Arthur KornbluthNew York$1.9M
- Maya SrivastavaWilliamsville$1.8M
- Melissa PalmerPlainview$1M
- Sonal KumarNew York$1M
- David PoppersNew York$939K
- Ellen ScherlNew York$857K
- Bruce SandsNew York$810K
- Jean Frederick ColombelNew York$786K
- Seth GrossNew York$624K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.